Form 4: Edwards Lifesciences Executive Reports Stock Transaction
SEC Form 4 Filing
Jean-Luc M Lemercier, a CVP at Edwards Lifesciences, reported a transaction involving common stock on May 11, 2024.
Summary
- On May 11, 2024, Jean-Luc M Lemercier, CVP of EMEACLA and JAPAC at Edwards Lifesciences Corp, engaged in a transaction involving the company's common stock.
- The transaction involved the disposal of 21 shares at a price of $86.72.
- Following the reported transaction, Lemercier beneficially owns 184,767.8055 shares of common stock directly.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock transaction by an executive, indicating a neutral sentiment.
Industry Context
This is a routine disclosure of a transaction by a company insider, which is a common occurrence for publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it involves a small number of shares compared to the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 05/11/2024 | Date of the stock transaction. |
| 05/13/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.